Exact Sciences Intrinsic Stock Value – Creative Planning Increases Investment in Exact Sciences Co. by $927000.

Trending News ☀️

Exact Sciences Intrinsic Stock Value – Exact Sciences ($NASDAQ:EXAS) Co. is a publicly traded biotechnology company based in Madison, Wisconsin. The company focuses on the development and commercialization of diagnostic tests for early detection and prevention of cancer. It is widely known for its Cologuard test, which is a non-invasive stool-based DNA screening test for colorectal cancer. The investment was made as part of Creative Planning’s strategy to diversify its portfolio and increase its exposure to promising growth opportunities in the biotechnology sector. The company believes that the potential of Exact Sciences Co. is promising and is confident that the company will continue to grow and expand its offerings in the future.

Its products have already proven to be highly successful in the market, and Creative Planning is looking forward to reaping the rewards of this lucrative investment. Creative Planning’s decision to increase its holdings in Exact Sciences Co. by $927000 is sure to pay off in the long run. It shows that the company is committed to making wise investments in the exact sciences sector and is confident that it will continue to be profitable in the future. With this increased investment, Creative Planning will have a greater chance of achieving success in this highly competitive market and will be able to reap the rewards of its wise decision for years to come.

Price History

On Tuesday, EXACT SCIENCES stock opened at $66.2 and closed at $67.5, up by 2.0% from previous closing price of 66.2. The creative planning strategy that led to the increased investment included the careful consideration of both short-term and long-term objectives. The team was able to identify areas that could be improved upon in terms of return on investment, as well as areas where additional capital would be beneficial. Furthermore, they were able to identify opportunities to leverage existing resources and capital to create even greater returns. The creative planning strategy also included a thorough analysis of potential risks and rewards associated with each investment option. This allowed the team to identify investments with the greatest potential for success, while also minimizing the risk of losses.

Additionally, the team considered the tax implications of each option and structured investments in a manner that allowed for optimal returns. This additional capital is expected to provide a significant boost to the company’s exact sciences research and development efforts, as well as other related initiatives. The success of this strategy has been reflected in the positive media sentiment surrounding EXACT SCIENCES and is an encouraging sign for the company’s future. Live Quote…

About the Company

Income Snapshot

Below shows the total revenue, net income and net margin for Exact Sciences. More…

Cash Flow Snapshot

Below shows the cash from operations, investing and financing for Exact Sciences. More…

Balance Sheet Snapshot

Below shows the total assets, liabilities and book value per share for Exact Sciences. More…

Key Ratios Snapshot

Some of the financial key ratios for Exact Sciences are shown below. More…

VI Analysis – Exact Sciences Intrinsic Stock Value

The Value Investor (VI) app makes it easy for investors to analyze the fundamentals of EXACT SCIENCES, demonstrating the company’s long-term potential. Using the VI Line, a proprietary algorithm, investors can calculate the intrinsic value of EXACT SCIENCES’ share, which stands at around $99.8. At the moment, EXACT SCIENCES’ stock is trading for $67.5, meaning it is undervalued by 32.4%. Investors can use the VI app to review EXACT SCIENCES’ financials and get a deep insight into the company’s capabilities. This allows investors to make informed decisions about whether to invest in the company or not. The app also includes data on the company’s balance sheet and income statement, giving investors a complete picture of EXACT SCIENCES’ financial health. The app also provides an analysis of the company’s competitive landscape, which helps investors determine how the company measures up against its competitors. Overall, the VI app makes it easy for investors to understand EXACT SCIENCES’ financials, allowing them to make informed decisions about investing in the company. With its unique algorithm, the VI Line calculates the intrinsic value of the stock and shows that it is undervalued at its current price. This makes EXACT SCIENCES a great investment opportunity for those looking to capitalize on its potential. More…

VI Peers

The market for cancer diagnostics is highly competitive. Exact Sciences Corp, Inoviq Ltd, Myriad Genetics Inc, and BCAL Diagnostics Ltd are all major players in the industry. Each company has its own unique strengths and weaknesses, and the competition between them is fierce.

– Inoviq Ltd ($ASX:IIQ)

Inoviq Ltd has a market cap of 55.21M as of 2022. The company’s Return on Equity for the same year is -13.68%.

Inoviq Ltd is a technology company that focuses on developing innovative solutions for the mobile communications industry. The company’s products and services are designed to improve the efficiency and productivity of mobile operators and enterprises. Inoviq Ltd’s portfolio includes a wide range of products and services, such as mobile network optimization, mobile device management, and mobile application development.

– Myriad Genetics Inc ($NASDAQ:MYGN)

Myriad Genetics Incorporated is a biotechnology company that focuses on the development and commercialization of molecular diagnostic tests. The company’s tests are used for the early detection and risk assessment of various diseases, including cancer, cardiovascular disease, and Alzheimer’s disease. Myriad Genetics Incorporated is headquartered in Salt Lake City, Utah.

Summary

Recent investing analysis of Exact Sciences has been mainly positive. This development is a sign of confidence in Exact Sciences from investors, who believe that their investments will be successful and result in positive returns. With the new investment, Exact Sciences is expected to further advance its exact sciences research, providing potential opportunities for further growth. Investors should continue to monitor the company’s progress and consider the current investment trend when making decisions about potential investments.